Form 4: REGENXBIO Director Jennifer Zachary Receives Significant Equity Compensation Awards

REGENXBIO Inc. Director Jennifer Zachary was granted 7,768 restricted stock units and options to purchase 39,815 shares of common stock on May 30, 2025, as part of her compensation package.

Summary

• Jennifer Zachary, a Director of REGENXBIO Inc. (RGNX), was granted equity awards on May 30, 2025.
• She acquired 7,768 shares of common stock through a time-based restricted stock unit (RSU) award, which will vest 100% on May 1, 2026, subject to her continuous service to the Issuer.
• Additionally, she was granted stock options to purchase 39,815 shares of common stock with an exercise price of $8.85 per share.
• These stock options will vest in 12 equal monthly installments following May 30, 2025, also contingent on her continuous service, and will expire on May 30, 2035.
• Following these transactions, Jennifer Zachary directly beneficially owns 22,064 shares of common stock and 39,815 stock options.

Sentiment

Score: 6

Explanation: The document reports routine equity compensation for a director, which is a positive for aligning interests and retention but does not directly reflect operational performance. It's a neutral-to-slightly positive event in terms of corporate governance.

Positives

• Director Jennifer Zachary received significant equity compensation, which aligns her financial interests with those of the company's shareholders.
• The compensation package includes both restricted stock units and stock options, providing a balanced incentive structure for both retention and long-term performance.
• The vesting schedules for both awards are tied to continuous service, encouraging the director's sustained commitment to the company.

Risks

• The vesting of both the restricted stock units and stock options is contingent upon Jennifer Zachary's continuous service to REGENXBIO Inc.; if her service terminates before vesting, unvested portions of the awards may be forfeited.

Future Outlook

The grants of restricted stock units and stock options with future vesting dates indicate an expectation of continued service from Director Jennifer Zachary and align her long-term incentives with the company's performance and strategic objectives.

Industry Context

Equity compensation, including restricted stock units and stock options, is a prevalent practice across various industries, particularly in the biotechnology sector where REGENXBIO operates. This approach is widely used to attract, retain, and incentivize key personnel, including directors, by aligning their financial interests with the long-term creation of shareholder value. This filing represents a routine compensation event for a director within the biotech industry.

Comparison to Industry Standards

• The use of both restricted stock units (RSUs) and stock options for director compensation is a common and widely accepted practice in publicly traded companies, especially within the biotechnology sector like REGENXBIO.
• Service-based vesting conditions, as seen in these awards, are standard mechanisms to ensure long-term commitment and alignment of interests between directors and shareholders.
• While the specific quantum of compensation varies based on company size, market capitalization, performance, and individual roles, the structure of these equity awards is consistent with typical industry standards for director compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: The equity grants align the director's interests with shareholders, potentially fostering better long-term decision-making and value creation.
• Employees: No direct impact on general employees is mentioned in this filing.

Next Steps

• Jennifer Zachary's continued service to REGENXBIO Inc. is required for the vesting of her equity awards.
• Future Form 4 filings will report any subsequent changes in Jennifer Zachary's beneficial ownership of REGENXBIO securities.

Key Dates

Keywords

REGENXBIO, RGNX, SEC Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, Stock Options, Director Compensation, Equity Awards, Biotechnology